Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Transforming Healthcare with AI: YiduTech's Gong Rujing at Summer Davos


DALIAN, China, June 30, 2024 /PRNewswire/ -- "AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New Champions, also known as Summer Davos, in Dalian, Ms. Gong Rujing (Yingying), Chairwoman and Founder of Yidu Tech, was invited as a distinguished representative of the healthcare technology sector. She shared her unique insights into the future of AI in healthcare during the thematic dialogue on "Healthcare Analytics, Not Moving Fast Enough."

This year marks the 10th anniversary of Yidu Tech and Ms. Gong Rujing's decade-long dedication to the healthcare industry. "I will continue this mission for decades to come and strive to do even better," she stated. From the inception of her entrepreneurial journey 10 years ago, she has been driven by the mission to leverage the power of technology to deliver precise healthcare to every individual.

Ms. Gong described the past decade as a journey filled with miracles and achievements. During this period, Yidu Tech has progressively established close collaborations with key stakeholders in the healthcare industry, including government agencies, hospitals, pharmaceutical companies, insurance firms, experts, and clinicians. As of March 31, 2024, Yidu Tech's "AI Medical Brain" YiduCore has been authorized to process and analyze over 5 billion medical records, covering more than 2,500 hospitals. Leveraging YiduCore's accumulated understanding of AI technology and medical knowledge, Yidu Tech and its partners are jointly driving innovation and progress in the healthcare field.

In regional population health management, Yidu Tech has assisted in constructing urban "health brains," with several benchmark projects implemented in cities such as Beijing and Ningbo. In AI-powered clinical research, Yidu Tech has supported researchers and clinicians in producing over 240 high-level papers, accelerating the application of research outcomes. Additionally, Yidu Tech provides clinical trial services to globally renowned pharmaceutical companies, helping them optimize trial processes, reduce costs, and bring new drugs to market more swiftly, ultimately benefiting patients. In healthcare management, Yidu Tech's AI technology plays a crucial role by analyzing vast amounts of medical data to provide comprehensive decision support to healthcare administrators, helping them optimize resource allocation and improve service efficiency. The number of active users on Yidu Tech's health management platform, each completing at least one transaction, has reached nearly 27.6 million. "These achievements are all empowered by medical data analysis and AI technology."

"We are now entering a new era of AI technology." The development of large language model technologies has opened up new possibilities across various industries. Yidu Tech has independently developed a large model specific to the medical field and is advancing its application across the entire healthcare industry chain, including medicine, pharmaceuticals, insurance, and patients. The goal is to promote further progress and innovation through new AI technologies. However, Ms. Gong also emphasized that the healthcare industry is professional, complex, and sensitive, and the application of new technologies must address challenges such as data security, privacy protection, and ethics.

"Data security and privacy protection are fundamental to the development of AI technology and medical big data technology. We must ensure that all stakeholders are satisfied with compliance, security, accessibility, and privacy protection." She illustrated this point with a vivid example: "If a patient is in a coma and in critical condition, unable to express their wishes, should the doctor immediately access their medical records without the patient's consent? This requires deep consideration and balance."

"AI technology still has a long way to go." She called on policymakers, healthcare institutions, and technology companies to work together to realize the immense potential of healthcare data. Ms. Gong highlighted that building trust is key, and enhancing data operability is essential to fully unleash the power of data. "It's not just about better data quality; it's about a better future for health."

Joining Ms. Gong in the dialogue were Professor Chong Yap Seng, Dean of the Yong Loo Lin School of Medicine at the National University of Singapore; Dr. Brandon Suh, CEO of Lunit; and Dr. Angela Wang Nan, Senior Vice President and Chief Investment Officer of Neusoft Group, and Chairman and President of Neusoft Europe.

SOURCE Yidu Tech


These press releases may also interest you

30 jun 2024
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
On June 27, 2024, Yidu Tech Inc. (the ''Company'' or ''Yidu Tech'') (2158.HK), a leader in China's AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million....

30 jun 2024
Yidu Tech Inc. ("Yidu Tech" or the "Company", together with its subsidiaries and consolidated affiliated entities, the "Group", HKEX: 2158) announced its annual results for the fiscal year ended 31 March 2024 ("FY2024" or the "Reporting Period"). The...

30 jun 2024
CBC Group ("CBC"), Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its controlled portfolio company, Hasten Biopharmaceutical ("Hasten"), an innovation-driven biopharmaceutical company, has...



News published on and distributed by: